A study highlighted S100A1’s ability to restore calcium cycling in cardiomyocytes, improving contractility in heart failure models, and gene therapy using AAV-S100A1 showed reduced fibrosis and hypertrophy in rodents (Rostami et al., 2025). Here, S100A1 is linked to heart failure.